|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021747,
umls-concept:C0030705,
umls-concept:C0063695,
umls-concept:C0087111,
umls-concept:C0220847,
umls-concept:C0229671,
umls-concept:C0341439,
umls-concept:C0439849,
umls-concept:C0441889,
umls-concept:C0445223,
umls-concept:C0871261,
umls-concept:C1514475,
umls-concept:C1552599,
umls-concept:C1704632,
umls-concept:C1704787,
umls-concept:C1706817,
umls-concept:C1749467,
umls-concept:C2911692
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-4-13
|
|
pubmed:abstractText |
Intercellular adhesion molecule 1 (ICAM-1) is a marker of inflammation and tissue damage. Levels of soluble ICAM-1 (sICAM-1) were measured in 71 patients with chronic C hepatitis treated with interferon (IFN)-alpha-2a, at baseline and at every 3 months of therapy, and in 42 normal control subjects. The levels of sICAM-1 were significantly higher in the patient than in the control subject group, particularly among cirrhotics. Baseline sICAM-1 levels were similar in responders and nonresponders. By contrast, the concentration of sICAM-1 decreased significantly only in responders during the first 3 months of therapy. The probability of response to treatment, analyzed by Kaplan-Meier analysis, was much higher in the group showing a decrease of sICAM-1 than in the patients who did not show such a decrease. In conclusion, a "longitudinal" evaluation of serum levels of sICAM-1 in the first period of treatment is particularly useful in the identification of patients with high significant probability of response to treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
181
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
425-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10669322-Adolescent,
pubmed-meshheading:10669322-Adult,
pubmed-meshheading:10669322-Aged,
pubmed-meshheading:10669322-Alanine Transaminase,
pubmed-meshheading:10669322-Antiviral Agents,
pubmed-meshheading:10669322-Biological Markers,
pubmed-meshheading:10669322-Female,
pubmed-meshheading:10669322-Hepacivirus,
pubmed-meshheading:10669322-Hepatitis C, Chronic,
pubmed-meshheading:10669322-Humans,
pubmed-meshheading:10669322-Intercellular Adhesion Molecule-1,
pubmed-meshheading:10669322-Interferon-alpha,
pubmed-meshheading:10669322-Liver,
pubmed-meshheading:10669322-Liver Cirrhosis,
pubmed-meshheading:10669322-Male,
pubmed-meshheading:10669322-Middle Aged,
pubmed-meshheading:10669322-Prognosis,
pubmed-meshheading:10669322-RNA, Viral,
pubmed-meshheading:10669322-Recombinant Proteins,
pubmed-meshheading:10669322-Severity of Illness Index,
pubmed-meshheading:10669322-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment.
|
|
pubmed:affiliation |
Dipartimento di Medicina e Sanità Pubblica, Università di Verona, Medicina Interna A, Policlinico Borgo Roma, 37134 Verona, Italy. capra@cmib.univr.it
|
|
pubmed:publicationType |
Journal Article
|
